EC
HRTX icon

Estate Counselors’s Heron Therapeutics HRTX Stock Holding History

Estate Counselors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-17,000
Closed -$28.9K – 130
2023
Q4 		$28.9K Hold
17,000
– – ﹤0.01% 118
2023
Q3 		$17.5K Hold
17,000
– – ﹤0.01% 124
2023
Q2 		$19.7K Buy
+17,000
New +$30.3K ﹤0.01% 124
2022
Q4 		– Sell
-3,000
Closed -$12K – 159
2022
Q3 		$12K Hold
3,000
– – ﹤0.01% 160
2022
Q2 		$8K Hold
3,000
– – ﹤0.01% 162
2022
Q1 		$17K Hold
3,000
– – ﹤0.01% 159
2021
Q4 		$27K Hold
3,000
– – ﹤0.01% 161
2021
Q3 		$32K Hold
3,000
– – ﹤0.01% 169
2021
Q2 		$46K Hold
3,000
– – 0.01% 161
2021
Q1 		$49K Buy
+3,000
New +$53.5K 0.01% 157
2020
Q3 		– Sell
-3,000
Closed -$44K – 130
2020
Q2 		$44K Buy
+3,000
New +$49.3K 0.01% 143

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Estate Counselors's HRTX Position: Q1 2024 in Review

Estate Counselors sold out of Heron Therapeutics (HRTX) in Q1 2024, closing a stake of 17,000 shares — an estimated $28.9K sold.

Estate Counselors first reported a position in HRTX in Q2 2020 and held it in 11 quarters. The position peaked at $49K in Q1 2021. 161 funds tracked by Wall St. Rank hold HRTX as of Q1 2024.

  • Estate Counselors reported no remaining Heron Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Estate Counselors sold 17,000 Heron Therapeutics shares in Q1 2024, an estimated $28.9K.
  • Estate Counselors first reported a position in Heron Therapeutics in Q2 2020 and held it in 11 quarters.
  • Estate Counselors's Heron Therapeutics position peaked at $49K in Q1 2021.
  • 161 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2024.

Based on Estate Counselors's 13F filing for Q1 2024, filed 14 May 2024.